Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis (ReBUILD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02040298
Recruitment Status : Completed
First Posted : January 20, 2014
Last Update Posted : April 18, 2016
Information provided by (Responsible Party):
University of California, San Francisco